HWM
SMMT icon

Hemington Wealth Management’s Summit Therapeutics SMMT Stock Holding History

Hemington Wealth Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$1K Sell
72
-21
-23% -$509 ﹤0.01% 1488
2025
Q2 		$1K Buy
93
+25
+37% +$570 ﹤0.01% 1460
2025
Q1 		$1K Buy
68
+63
+1,260% +$1.26K ﹤0.01% 1453
2024
Q4 		$0 Buy
+5
New +$97 ﹤0.01% 1761

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
ACL
APEIRON Capital Ltd Hong Kong $107M AUM 9.59% 1-Year Est. Return

Hemington Wealth Management's SMMT Position: Q3 2025 in Review

Hemington Wealth Management reduced its Summit Therapeutics (SMMT) stake by 23% in Q3 2025, selling an estimated $509 and leaving 72 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1488.

Hemington Wealth Management first reported a position in SMMT in Q4 2024 and has held it in 4 quarters since. 232 funds tracked by Wall St. Rank hold SMMT as of Q3 2025.

  • Hemington Wealth Management held 72 shares of Summit Therapeutics worth $1K as of Q3 2025.
  • Hemington Wealth Management sold 21 Summit Therapeutics shares in Q3 2025, an estimated $509.
  • Summit Therapeutics made up ﹤0.01% of Hemington Wealth Management's portfolio in Q3 2025, its #1488 holding.
  • Hemington Wealth Management first reported a position in Summit Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 232 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2025.

Based on Hemington Wealth Management's 13F filing for Q3 2025, filed 24 Oct 2025.